Waktu Inisiasi Farmakoterapi Hepatitis B Kronis

Oleh :

Debtia Rahmah

Waktu untuk memulai farmakoterapi pada hepatitis B kronik adalah pengetahuan yang penting bagi dokter, karena infeksi virus hepatitis B masih menjadi masalah kesehatan dunia. Walaupun prevalensi hepatitis B telah menurun dengan adanya vaksinasi, tetapi secara global masih terdapat 350–400 juta orang yang terkena hepatitis B kronik.[1]

Indonesia merupakan negara dengan prevalensi hepatitis B terbesar kedua di Asia Tenggara, setelah Vietnam. Berdasarkan riset kesehatan dasar (riskesdas) tahun 2018, sebanyak 7,1% penduduk Indonesia mengalami hepatitis B kronik. Tingginya morbiditas dan mortalitas yang ditimbulkan hepatitis B menjadi faktor penting untuk memberikan terapi pada saat yang tepat.[2,3]

Terapi Antiviral Menekan Replikasi HBV dan Menurunkan Morbiditas

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Tripathi N, Mousa OY. Hepatitis B. StatPearls Publishing. 2022 https://www.ncbi.nlm.nih.gov/books/NBK555945/
2. Kurniawan J. Perkembangan Terapi Hepatitis B Kronis di Indonesia. Jurnal Penyakit Dalam Indonesia. 2021;8(3). http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/632/277
3. Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
4. Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat? Liver Int. 2018 Feb;38 Suppl 1:71-78. doi: 10.1111/liv.13631.
5. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2018 Nov 15;3(1):8-19. doi: 10.1002/hep4.1281.
6. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carci‐ noma in untreated subjects with chronic hepatitis B: a systematic re‐ view and meta-analysis. Liver Int. 2016;36:1239-1251.
7. Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician. 2019 Mar 1;99(5):314-323.
8. Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: Targets and Future Therapies. Int J Mol Sci. 2020 Dec 28;22(1):213. doi: 10.3390/ijms22010213.
9. García-López M, Lens S, Pallett LJ, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol. 2021 May;74(5):1064-1074. doi: 10.1016/j.jhep.2020.11.043.\
10. European Association for the Study of the Liver EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
11. Papatheodoridis G.V., Manolakopoulos S., Su T.H., Siakavellas S., Liu C.J., Kourikou A. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology. 2018;68:415–424.
12. Lok ASF, Mcmahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.
13. Zhou J, Wang FD, Wang ML, et al. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne). 2021 Aug 30;8:717125. doi: 10.3389/fmed.2021.717125.
14. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-283.
15. WHO. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015 Mar. https://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059_eng.pdf